Nicole L. Kallewaard

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Potently neutralizing and protective human antibodies against SARS-CoV-2”.

Potently neutralizing and protective human antibodies against SARS-CoV-2

Nature(2020)10.1038/s41586-020-2548-6

N/A

14.8DataRank · unranked

1192 citations

Pavlo Gilchuk, James Brett Case, Elad Binshtein, Rita E. Chen, Joseph P. Nkolola +36 more

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.22.111005

N/A

0DataRank · unranked

51 citations

Pavlo Gilchuk, James Brett Case, Elad Binshtein, Rita E. Chen, Joseph X. Reidy +26 more

The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination

medRxiv(2021)10.1101/2021.12.15.21267605

N/A

0DataRank · unranked

6 citations

Jay Tuttle, Lin Zhang, Josh Poorbaugh, Nicole L. Kallewaard, Peter Vaillancourt +11 more

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Cell Reports(2022)10.1016/j.celrep.2022.110812

N/A

0DataRank · unranked

464 citations

Stefanie Žentelis, Lingshu Wang, Denisa Foster, Peter Vaillancourt, Matthew Wiggin +64 more

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

UNC Libraries(2022)10.17615/77w4-hz26

N/A

0DataRank · unranked

1 citations

Nicole L. Kallewaard, Stephanie Beasley, Montanea Daniels, Joshua J. Freitas, Robert J. Benschop +11 more